The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Adoptive Transfer of Epstein-Barr Virus (EBV) Nuclear Antigen 1–Specific T Cells As Treatment for EBV Reactivation and Lymphoproliferative Disorders After Allogeneic Stem-Cell Transplantation
Open accessAbstract
Purpose: Reactivation of Epstein-Barr virus (EBV) after allogeneic stem-cell transplantation (SCT) can lead to severe life-threatening infections and trigger post-transplantation lymphoproliferative disease (PTLD). Since EBV-specific T cells could prevent PTLD, cellular immunotherapy has been a promising treatment option. However, generation of antigen-specific T-cell populations has been difficult within a short time frame. Patients and Methods: To improve availability in urgent clinical conditions, we developed a rapid protocol for isolation of polyclonal EBV nuclear antigen 1 (EBNA-1) –specific T cells by using an interferon gamma (IFN-γ) capture technique. Results: We report on the use of adoptive transfer of EBNA-1–specific T cells in 10 pediatric and adult patients with EBV viremia and/or PTLD after SCT. No acute toxicity or graft-versus-host disease (GVHD) of more than grade 2 occurred as a result of adoptive T-cell transfer. In vivo expansion of transferred EBNA-1–specific T cells was observed in eight of 10 patients after a median of 16 days following adoptive transfer that was associated with clinical and virologic response in seven of them (70%). None of the responders had EBV-associated mortality. Within clinical responders, three patients were disease free by the day of last follow-up (2 to 36 months), three patients died of other infectious complications, and one patient died as a result of relapse of malignancy. EBV-related mortality was observed in two of 10 patients, and another patient had ongoing viremia without clinical symptoms at last follow-up. Conclusion: Adoptive ex vivo transfer of EBNA-1–specific T cells is a feasible and well-tolerated therapeutic option, representing a fast and efficient procedure to achieve reconstitution of antiviral T-cell immunity after SCT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epstein–Barr virus: 40 years on
Young, L. S., & Rickinson, A. B. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1452 · Cited by 2,227
Restoration of Viral Immunity in Immunodeficient Humans by the Adoptive Transfer of T Cell Clones
Riddell, S. R., Watanabe, K. S., Goodrich, J. M., Li, C. R., Agha, M. E., & Greenberg, P. D. (1992) · Science · doi:10.1126/science.1352912 · Cited by 1,201
Rooney, C. M., Smith, C. A., Ng, C. Y. C., Loftin, S. K., Sixbey, J. W., Gan, Y., Srivastava, D.-K., Bowman, L. C., Krance, R. A., Brenner, M. K., et al. (1998) · Blood · doi:10.1182/blood.v92.5.1549 · Cited by 1,135
Gattinoni, L. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24480 · Cited by 958
Helping the CD8+ T-cell response
Bevan, M. J. (2004) · Nature Reviews Immunology · doi:10.1038/nri1413 · Cited by 797
Heslop, H. E., Slobod, K. S., Pule, M. A., Hale, G. A., Rousseau, A., Smith, C. A., Bollard, C. M., Liu, H., Wu, M.-F., Rochester, R. J., et al. (2010) · Blood · doi:10.1182/blood-2009-08-239186 · Cited by 780
Sun, J. C., Williams, M. A., & Bevan, M. J. (2004) · Nature Immunology · doi:10.1038/ni1105 · Cited by 649
Leen, A. M., Myers, G. D., Sili, U., Huls, M. H., Weiss, H., Leung, K. S., Carrum, G., Krance, R. A., Chang, C.-C., Molldrem, J. J., et al. (2006) · Nature Medicine · doi:10.1038/nm1475 · Cited by 545
Feuchtinger, T., Opherk, K., Bethge, W. A., Topp, M. S., Schuster, F. R., Weissinger, E. M., Mohty, M., Or, R., Maschan, M., Schumm, M., et al. (2010) · Blood · doi:10.1182/blood-2010-01-262089 · Cited by 435
Self-citationFeuchtinger, T., Matthes‐Martin, S., Richard, C., Lion, T., Fuhrer, M., Hamprecht, K., Handgretinger, R., Peters, C., Schuster, F. R., Beck, R., et al. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06108.x · Cited by 394
Self-citation
Cited by
The Immunology of Epstein-Barr Virus–Induced Disease
Taylor, G. S., Long, H. M., Brooks, J. M., Rickinson, A. B., & Hislop, A. D. (2015) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112326 · Cited by 602
Bollard, C. M., Gottschalk, S., Torrano, V., Diouf, O., Ku, S., Hazrat, Y., Carrum, G., Ramos, C., Fayad, L., Shpall, E. J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.5304 · Cited by 503
Tzannou, I., Papadopoulou, A., Naik, S., Leung, K., Martinez, C. A., Ramos, C. A., Carrum, G., Sasa, G., Lulla, P., Watanabe, A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.0655 · Cited by 457
Papadopoulou, A., Gerdemann, U., Katari, U. L., Tzannou, I., Liu, H., Martinez, C., Leung, K., Carrum, G., Gee, A. P., Vera, J. F., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008825 · Cited by 402
Virus-Specific T Cells for the Immunocompromised Patient
Houghtelin, A., & Bollard, C. M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01272 · Cited by 90
Metadata
- Authors
- Icheva, V., Kayser, S., Wolff, D., Tuve, S., Kyzirakos, C., Bethge, W., Greil, J., Albert, M. H., Schwinger, W., Nathrath, M., Schumm, M., Stevanovic, S., Handgretinger, R., Lang, P., & Feuchtinger, T.
- Venue
- Journal of Clinical Oncology
- Published
- 2013-01-01
- Volume
- 31
- Issue
- 1
- Pages
- 39-48
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2139450265
- Cited by
- 268
- References
- 31
- FWCI
- 10.65
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adoptive Transfer of Epstein-Barr Virus (EBV) Nuclear Antigen 1–Specific T Cells As Treatment for EBV Reactivation and Lymphoproliferative Disorders After Allogeneic Stem-Cell Transplantation. https://app.cochat.ai/papers/10.1200/jco.2011.39.8495
- The paper
- Icheva, V., Kayser, S., Wolff, D., Tuve, S., Kyzirakos, C., Bethge, W., Greil, J., Albert, M. H., Schwinger, W., Nathrath, M., Schumm, M., Stevanovic, S., Handgretinger, R., Lang, P., & Feuchtinger, T. (2013). Adoptive Transfer of Epstein-Barr Virus (EBV) Nuclear Antigen 1–Specific T Cells As Treatment for EBV Reactivation and Lymphoproliferative Disorders After Allogeneic Stem-Cell Transplantation. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2011.39.8495
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.